Xeris Biopharma Holdings (XERS) Current Assets (2020 - 2026)

Xeris Biopharma Holdings has reported Current Assets for 7 years, with the latest figure at $251.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 53.94% year-over-year to $251.7 million; the trailing twelve-month figure through Mar 2026 stood at $251.7 million (up 53.94% YoY), and the FY2025 full-year result was $240.3 million, up 43.33% from the prior year.
• Current Assets for Q1 2026 stood at $251.7 million, up from $240.3 million in the prior quarter.
• The five-year high for Current Assets was $251.7 million in Q1 2026, with the low at $148.9 million in Q3 2022.
• Historically, Current Assets has averaged $179.4 million across 5 years, with a median of $167.7 million in 2024.
• Annual changes were most pronounced in 2023 — Current Assets dropped 16.35% — and 2026, when it soared 53.94%.
• Xeris Biopharma Holdings' Current Assets stood at $186.8 million in 2022, then decreased by 16.35% to $156.3 million in 2023, then gained by 7.29% to $167.7 million in 2024, then jumped by 43.33% to $240.3 million in 2025, then gained by 4.73% to $251.7 million in 2026.
• The last three Current Assets figures came in at $251.7 million (Q1 2026), $240.3 million (Q4 2025), and $224.0 million (Q3 2025), per Business Quant data.